CHDI
Listed here are over 950 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Casula EP, Mayer IMS, Desikan M, Tabrizi SJ, Rothwell JC, Orth M
Motor cortex synchronization influences the rhythm of motor performance in premanifest Huntington's disease
Sepers MD, Smith-Dijak A, LeDue J, Kolodziejczyk K, Mackie K, Raymond LA
Endocannabinoid-specific impairment in synaptic plasticity in striatum of Huntington's disease mouse model
Langfelder P, Gao F, Wang N, Howland D, Kwak S, Vogt TF, Aaronson JS, Rosinski J, Coppola G, Horvath S, Yang XW
MicroRNA signatures of endogenous Huntingtin CAG repeat expansion in mice
Carlozzi NE, Hahn EA, Frank SA, Perlmutter JS, Downing ND, McCormack MK, Barton S, Nance MA, Schilling SG, HDQLIFE Site Investigators and Coordinators
A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning
Conforti P, Besusso D, Bocchi VD, Faedo A, Cesana E, Rossetti G, Ranzani V, Svendsen CN, Thompson LM, Toselli M, Biella G, Pagani M, Cattaneo E
Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes
Proc Natl Acad Sci USA
January 8, 2018
115 (4) :E762-E771
115 (4) :E762-E771
PMID: 29311338
Mestre TA, Forjaz MJ, Mahlknecht P, Cardoso F, Ferreira JJ, Reilmann R, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT, Members of the Movement Disorder Society Committee on Rating Scales Development
Rating scales for motor symptoms and signs in Huntington's disease: Critique and recommendations
Mov Disord Clin Pract
January 3, 2018
5 (2) :111-117
5 (2) :111-117
PMID: 30363393
PMCID: 6174417
DOI: 10.1002/mdc3.12571
Wang HB, Loh DH, Whittaker DS, Cutler T, Howland D, Colwell CS
Time-restricted feeding improves circadian dysfunction as well as motor symptoms in the Q175 mouse model of Huntington's disease
Al-Ramahi I, Panapakkam Giridharan SS, Chen YC, Patnaik S, Safren N, Hasegawa J, de Haro M, Wagner Gee AK, Titus SA, Jeong H, Clarke J, Krainc D, Zheng W, Irvine RF, Barmada S, Ferrer M, Southall N, Weisman LS, Botas J, Marugan JJ
Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein
Hensman Moss DJ, Robertson N, Farmer R, Scahill RI, Haider S, Tessari MA, Flynn G, Fischer DF, Wild EJ, Macdonald D, Tabrizi SJ
Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays
Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ, TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators
Motor, cognitive, and functional declines contribute to a single progressive factor in early HD
Fodale V, Boggio R, Daldin M, Cariulo C, Spiezia MC, Byrne LM, Leavitt BR, Wild EJ, Macdonald D, Weiss A, Bresciani A
Validation of ultrasensitive mutant Huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay
Dickey AS, Sanchez DN, Arreola M, Sampat KR, Fan W, Arbez N, Akimov S, Van Kanegan MJ, Ohnishi K, Gilmore-Hall SK, Flores AL, Nguyen JM, Lomas N, Hsu CL, Lo DC, Ross CA, Masliah E, Evans RM, La Spada AR
PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis
Arbez N, Ratovitski T, Roby E, Chighladze E, Stewart JC, Ren M, Wang X, Lavery DJ, Ross CA|
Post-translational modifications clustering within proteolytic domains decrease mutant huntingtin toxicity
Friedman A, Homma D, Bloem B, Gibb LG, Amemori KI, Hu D, Delcasso S, Truong TF, Yang J, Hood AS, Mikofalvy KA, Beck DW, Nguyen N, Nelson ED, Toro Arana SE, Vorder Bruegge RH, Goosens KA, Graybiel AM
Chronic stress alters striosome-circuit dynamics, leading to aberrant decision-making
Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, Reilmann R, Landwehrmeyer B, Gregory S, Scahill RI, Langbehn DR, Tabrizi SJ, Track-HD and Track-On Investigators
Survival end points for Huntington disease trials prior to a motor diagnosis
Chao MJ, Gillis T, Atwal RS, Mysore JS, Arjomand J, Harold D, Holmans P, Jones L, Orth M, Myers RH, Kwak S, Wheeler VC, MacDonald ME, Gusella JF, Lee JM
Haplotype-based stratification of Huntington's disease
Brown KE, Lohse KR, Mayer IMS, Strigaro G, Desikan M, Casula EP, Meunier S, Popa T, Lamy JC, Odish O, Leavitt BR, Durr A, Roos RAC, Tabrizi SJ, Rothwell JC, Boyd LA, Orth M
The reliability of commonly used electrophysiology measures
Arnerić SP, Cedarbaum JM, Khozin S, Papapetropoulos S, Hill DL, Ropacki M, Rhodes J, Dacks PA, Hudson LD, Gordon MF, Kern VD, Romero K, Vradenburg G, Au R, Karlin DR, Facheris MF, Fitzer-Attas CJ, Vitolo OV, Wang J, Miller BM, Kaye JA
Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem
Wild EJ, Tabrizi SJ
Therapies targeting DNA and RNA in Huntington's disease
Wu D, Faria AV, Younes L, Mori S, Brown T, Johnson H, Paulsen JS, Ross CA, Miller MI, PREDICT-HD InvestigatorsCoordinators of the Huntington Study Group
Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease
Whittaker DS, Wang HB, Loh DH, Cachope R, Colwell CS
Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease
Pharmacol Res Perspect
October 30, 2017
5 (5) :e00344
5 (5) :e00344
PMID: 28971617
PMCID: PMC5625154
DOI: 10.1002/prp2.344
Bondulich MK, Jolinon N, Osborne GF, Smith EJ, Rattray I, Neueder A, Sathasivam K, Ahmed M, Ali N, Benjamin AC, Chang X, Dick JRT, Ellis M, Franklin SA, Goodwin D, Inuabasi L, Lazell H, Lehar A, Richard-Londt A, Rosinski J, Smith DL, Wood T, Tabrizi SJ, Brandner S, Greensmith L, Howland D, Munoz-Sanjuan I, Lee SJ, Bates GP
Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice
Warner JB 4th, Ruff KM, Tan PS, Lemke EA, Pappu RV, Lashuel HA
Monomeric Huntingtin Exon 1 has similar overall structural features for wild-type and pathological polyglutamine lengths
Schuldenzucker V, Schubert R, Muratori LM, Freisfeld F, Rieke L, Matheis T, Schramke S, Motlik J, Kemper N, Radespiel U, Reilmann R
Behavioral testing of minipigs transgenic for the Huntington gene - A three-year observational study
Ghosh R, Tabrizi SJ
Gene suppression approaches to neurodegeneration
Lee JM, Chao MJ, Harold D, Abu Elneel K, Gillis T, Holmans P, Jones L, Orth M, Myers RH, Kwak S, Wheeler VC, MacDonald ME, Gusella JF
A modifier of Huntington's disease onset at the MLH1 locus
Bresciani A, Missineo A, Gallo M, Cerretani M, Fezzardi P, Tomei L, Cicero DO, Altamura S, Santoprete A, Ingenito R, Bianchi E, Pacifici R, Dominguez C, Munoz-Sanjuan I, Harper S, Toledo-Sherman L, Park LC
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)
Frost C, Mulick A, Scahill RI, Owen G, Aylward E, Leavitt BR, Durr A, Roos RAC, Borowsky B, Stout JC, Reilmann R, Langbehn DR, Tabrizi SJ, Sampaio C, TRACK-HD Investigators
Design optimization for clinical trials in early-stage manifest Huntington's disease
Niccolini F, Pagano G, Fusar-Poli P, Wood A, Mrzljak L, Sampaio C, Politis M
Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies
Hensman Moss DJ, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S, TRACK-HD investigators, REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study
Brady ST, Morfini GA
Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases
Westervelt HJ, Bernier RA, Faust M, Gover M, Bockholt HJ, Zschiegner R, Long JD, Paulsen JS, PREDICT-HD Investigators, Coordinators of the Huntington Study Group
Data quality assurance and control in cognitive research: Lessons learned from the PREDICT-HD study
Schain M, Fazio P, Mrzljak L, Amini N, Al-Tawil N, Fitzer-Attas C, Bronzova J, Landwehrmeyer B, Sampaio C, Halldin C, Varrone A
Revisiting the Logan plot to account for non-negligible blood volume in brain tissue
Ratovitski T, O’Meally RN, Jiang M, Chaerkady R, Chighladze E, Stewart JC, Wang X, Arbez N, Roby E, Alexandris A, Duan W, Vijayvargia R, Seong IS, Lavery DJ, Cole RN, Ross CA
Post-Translational Modifications (PTMs), identified on endogenous Huntingtin, cluster within proteolytic domains between HEAT repeats
Zheng P, Kozloski J
Striatal network models of Huntington's disease dysfunction phenotypes
Ghosh S, Sun Z, Li Y, Cheng Y, Mohan A, Sampaio C, Hu J
An exploration of latent structure in observational Huntington's disease studies
Dietrich P, Johnson IM, Alli S, Dragatsis I
Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis
Kalathur RKR, Pedro Pinto J, Sahoo B, Chaurasia G, Futschik ME
HDNetDB: A molecular interaction database for network-oriented investigations into Huntington's disease
Daldin M, Fodale V, Cariulo C, Azzollini L, Verani M, Martufi P, Spiezia MC, Deguire SM, Cherubini M, Macdonald D, Weiss A, Bresciani A, Vonsattel JG, Petricca L, Marsh JL, Gines S, Santimone I, Marano M, Lashuel HA. Squitieri F, Caricasole A
Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models
Kang H, Vázquez FX, Zhang L, Das P, Toledo-Sherman L, Luan B, Levitt M, Zhou R
Emerging β-sheet rich conformations in supercompact Huntingtin Exon-1 mutant structures